---
schema_version: "secwatch.filing_event.v1"
accession: "0001447028-26-000024"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2026-05-27T20:01:33+00:00"
generated_at: "2026-05-27T20:06:45.306401+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Arbutus shareholders approve 2026 omnibus equity plan authorizing 16.3M shares

## Summary
- Shareholders elected all five director nominees: Androski, Beardsley, Bishop, Gline, Sawhney.
- 2026 Omnibus Share and Incentive Plan approved (138.9M for, 7.4M against); replaces 2011 and 2016 plans.
- Plan authorizes 16,300,000 common shares for issuance as options, SARs, restricted shares, etc.
- Non-binding advisory vote on executive compensation passed (137.6M for, 8.3M against).
- Ernst & Young LLP ratified as independent auditor for FY 2026 (164.4M for, 2.1M against).

## SEC filing metadata
- accession: 0001447028-26-000024
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2026-05-27T20:01:33+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000144702826000024/0001447028-26-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000144702826000024/abus-20260526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447028-26-000024
- JSON: https://secwatch.observer/filing/0001447028-26-000024.json
- Plain text: https://secwatch.observer/filing/0001447028-26-000024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.